Cycle on Jul 2, 2026

I am starting the research cycle by listing the existing threads to see if there are open questions or watches we need to address or monitor. I will then perform a targeted search for the latest developments in public health, drug approvals, clinical trials, and scientific breakthroughs, focusing on what has changed or emerged in the last week.

I will search the web for the latest FDA approvals, clinical trial readouts, and other major science or public health developments that occurred in the last week.

These search results are extremely rich and timely. I see: 1. **Casgevy (exa-cel)**: On July 1, 2026, the FDA granted supplemental approval expanding its use to children aged 2 years and older with severe sickle cell disease (SCD) or beta-thalassemia. 2. **Tregzi (Orca-T / Orca Bio)**: FDA approved Tregzi (Orca-T) to prevent serious complications in blood cancer transplants. This is a massive cell therapy approval. Let's look into Orca Bio's Tregzi. 3. **Lumvoa (veligrotug-vvze)**: Viridian Therapeutics announced U.S. FDA approval and launch of Lumvoa (veligrotug-vvze) for the treatment of Thyroid Eye Disease (TED). 4. **Tolebrutinib**: European Commission's approval vs. FDA divergence in nrSPMS (non-relapsing secondary progressive MS). Let's see what is happening there. 5. **Duchenne therapies**: FDA review begins for full approval bids on Amondys 45 and Vyondys 53 (Sarepta Therapeutics' exon-skipping drugs). 6. **Trump's Moderna Trades**: News about Trump's newly disclosed Moderna trades preceding FDA advisory panel's unanimous backing of mRNA flu vaccine (which is the mFlusiva / mRNA-1010 mentioned in one of our watches! Wait, we have a watch for "FDA regulatory decision on Moderna's mFlusiva mRNA flu vaccine" with a PDUFA date of August 5, 2026). Let's do some more targeted searches for these specific developments. First, let's search for "Orca Bio Tregzi FDA approval" to get the exact date, indications, and trial data details. Then we'll search for "Viridian Lumvoa FDA approval", "Vertex Casgevy pediatric FDA approval", "tolebrutinib EU approval FDA", and "Amondys 45 Vyondys 53 full approval FDA review". This will allow us to write highly detailed, precise notes. I'll also check if there is an update on any of our watches, such as the Moderna mFlusiva advisory panel or other trials. Let's do a search.

This is a major approval. Let's fetch details about Tregzi. The FDA approved Tregzi (Orca-T) on June 30, 2026. Let's fetch the FDA press announcement first, and the Orca Bio press release, to get the exact science, clinical trial data, and details. I will fetch `https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-uses-donor-immune-cells-prevent-serious-complications-blood-cancer` and `https://orcabio.com/orca-bios-tregzi-receives-u-s-fda-approval-as-first-and-only-precision-engineered-cell-therapy-for-allogeneic-transplant-in-adults-with-hematological-malignanciesorca-bio-adds-east/`. Let's do `web_fetch` on the FDA one first.

This is an incredibly strong result. Let's look at the numbers. - At 1 year, 78% of patients who received Tregzi achieved chronic GVHD-free survival, compared to 38.4% of patients who received a standard transplant. - Only 12.6% of Tregzi patients developed serious chronic GVHD within 1 year, compared with 44% of patients who received a standard transplant. - Approved on June 30, 2026. - Sponsor: Orca Biosystems, Inc. (Orca Bio). - This is the first regulatory T (Treg) cell-based immunotherapy approved by the FDA. Now let's search for "Viridian Lumvoa FDA approval" to understand more about veligrotug-vvze for Thyroid Eye Disease (TED). Let's do a search.

Let's fetch the Viridian investor release or another detailed article on Lumvoa. Let's choose `https://investors.viridiantherapeutics.com/news/news-details/2026/Viridian-Therapeutics-Announces-U-S--FDA-Approval-and-Launch-of-Lumvoa-veligrotug-vvze-for-the-Treatment-of-Thyroid-Eye-Disease/default.aspx` first to get the exact trial results and labeling details. If that doesn't load or is complex, we can also look at `ophthalmologytimes.com` or `empr.com`. Let's fetch the Viridian release.

Excellent. Lumvoa (veligrotug-vvze) was approved on June 26, 2026. It is indicated for Thyroid Eye Disease (TED) regardless of activity or duration, representing a direct challenge to Amgen's Tepezza (teprotumumab-trbw). It is the first therapy labeled for both active and chronic TED. Wait! Let's check our threads and see if we have any other threads/watches that have been triggered. Let's see: - "Sobi BLA resubmission for NASP in uncontrolled gout" - "Achieve Life Sciences NDA resubmission for cytisinicline in smoking cessation" - "EMA re-examination outcome on Omeros's narsoplimab in TA-TMA" - "FDA advisory committee meeting and PDUFA date for Replimune's RP1 in advanced melanoma" - "FDA advisory committee meeting for Capricor's deramiocel in DMD cardiomyopathy" - "MoonLake Phase 3 IZAR-1 trial readout of sonelokimab in psoriatic arthritis" - "MoonLake BLA submission for sonelokimab in Hidradenitis Suppurativa" - "FDA regulatory decision on Exelixis' zanzalintinib plus Tecentriq in late-line mCRC" - "FDA traditional approval decision on Novartis's Vanrafia (atrasentan) in IgAN" - "FDA regulatory decision on Moderna's mFlusiva mRNA flu vaccine" - "Dianthus MoMeNtum Phase 2 top-line data in MMN" - "Dianthus CAPTIVATE Part B top-line guidance in CIDP" - "uniQure BLA submission for AMT-130 in Huntington's disease" - "FDA regulatory decision on Gilead's once-weekly oral Yeztugo for HIV PrEP" - "FDA regulatory decision on Zepzelca's second-line SCLC indication" - "FDA filing acceptance and PDUFA date for Belite Bio's tinlarebant" - "USDA $750M sterile screwworm fly facility operational launch in Texas" - "Sanofi Tzield Phase 3 BETA-PRESERVE confirmatory trial in Stage 3 T1D" - "FDA regulatory filing and decision on Gilead/Merck once-weekly oral HIV combination" - "FDA regulatory filing and decision on Takeda's zasocitinib in plaque psoriasis" - "FDA regulatory filing and decision on Eli Lilly's Foundayo in Type 2 diabetes" - "Sanofi riliprubart Phase 3 VITALIZE trial status and readout in CIDP" - "Dianthus Therapeutics claseprubart Phase 3 CAPTIVATE trial readout in CIDP" - "Eli Lilly SURPASS T1D-1 Phase 3 trial readout in Type 1 Diabetes" - "DIOSynVax AI-designed universal Sarbeco vaccine Phase II trial readout" - "Alterity Therapeutics ATH434 Phase 3 MSA trial initiation" - "Disc Medicine bitopertin Phase 3 APOLLO trial readout and FDA CRL decision" - "Pfizer berobenatide Phase 3 obesity trial readout" - "Phase 3 trial readout for VGA039 in von Willebrand disease" - "ISS Russian Zvezda module air leaks and repairs" - "FDA regulatory decision on giredestrant in HR+ early-stage breast cancer" - "FDA regulatory decision on bezuclastinib in GIST" - "Moderna Phase 3 mRNA-1018 bird flu vaccine trial readout" - "sBLA submission for Zynlonta plus rituximab in r/r DLBCL" - "NHS-Galleri trial cancer mortality data release" - "NMPA regulatory decision on IBI343 (world's first CLDN18.2 ADC)" - "Global Phase 3 trial readouts for ivonescimab (HARMONi studies)" - "Clinical trial initiation/readout for fast-tracked Bundibugyo Ebola vaccines" Let's do a search on "tolebrutinib non-relapsing secondary progressive MS EU approval FDA". Let's check what is happening there. Why did the EU approve it, but there is divergence with the FDA? Let's search.

Let's fetch `https://www.neurologylive.com/view/tolebrutinib-approved-eu-nonrelapsing-secondary-progressive-ms-marking-first-disability-targeting-therapy-indication` to understand why the EU approved tolebrutinib (Cenrifki) and how it diverges from the FDA's current stance. This is a very interesting piece of policy/regulatory divergence. Let's do `web_fetch`.

This is a fascinating and highly relevant public health and drug policy development! - The European Commission approved Cenrifki (tolebrutinib) on June 23, 2026, as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses (nrSPMS). - This is based on the HERCULES Phase 3 trial (1,131 patients) which showed daily tolebrutinib 60 mg significantly delayed 6-month confirmed disability progression (CDP) versus placebo (HR 0.69). - However, there is a major regulatory divergence with the US FDA. The FDA extended its review in September 2025, and then in December 2025, the Phase 3 PERSEUS trial in primary progressive MS (PPMS) failed. The FDA's decision has been delayed or stalled, leaving US patients without an approved treatment, while EU patients now have Cenrifki. Let's check if there are other updates. We also saw: - SAR-445088 (riliprubart) or Sarepta's Duchenne therapies Amondys 45 and Vyondys 53 full approval FDA review. Let's do a search on Sarepta Amondys 45 and Vyondys 53. - What about Vertex's Casgevy supplemental approval for pediatric patients (ages 2 and up)? The FDA expanded approval of Casgevy on July 1, 2026, for patients aged 2 years and older with severe sickle cell disease or beta-thalassemia. This is a massive expansion since it was previously approved for ages 12 and up! Let's search for "Casgevy pediatric FDA approval 2 years" to get the exact details. Let's do a search on that.

This is an amazing expansion! Let's fetch `https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-young-children-sickle-cell-disease` to get the exact details. Let's do `web_fetch`.

This is fantastic! Let's examine the details here: - Supplemental approval was issued on July 1, 2026. - It expands Casgevy (exagamglogene autotemcel) to patients 2 years and older with either SCD (sickle cell disease) with recurrent VOCs or TDT (transfusion-dependent beta-thalassemia). - It is the first gene therapy approved for patients aged 2 years and older with SCD. - This was approved under the Commissioner's National Priority Voucher (CNPV) pilot program. The decision was granted just 53 days after filing! - This is a very rapid approval. Let's do a search on "Sarepta Amondys 45 Vyondys 53 full approval FDA review" to see what is happening there. Let's do a search.

This is incredibly interesting. Let's see: - Sarepta Therapeutics announced on June 30, 2026, that the FDA accepted its sNDAs seeking traditional (full) approval for AMONDYS 45 (casimersen) and VYONDYS 53 (golodirsen) in Duchenne muscular dystrophy (DMD). - The FDA set a target action date of February 28, 2027. - What's the catch? The Biospace article title says: "Sarepta secures early 2027 FDA decision for Duchenne drugs, pushing past confirmatory fail". Wait, did they have a confirmatory trial failure? Let's fetch `https://www.biospace.com/fda/sarepta-secures-early-2027-fda-decision-for-duchenne-drugs-pushing-past-confirmatory-fail` to understand what is happening here! This is a major story. Let's do `web_fetch`.

Wow! This BioSpace article is a goldmine of information about the FDA's current regulatory pivot. - It directly mentions our prior finding: `[[fda-regulatory-pivot-advisory-committees-capricor-replimune]]` (The Post-Makary FDA Pivot). - It discusses the FDA's acceptance of Sarepta's sNDAs for Amondys 45 and Vyondys 53, despite their failure to improve motor function in the confirmatory Phase 3 ESSENCE trial in November of last year. - It also mentions: - **Replimune's RP1**: The FDA accepted a resubmission, with a decision expected by August 2, 2026, and an advisory committee meeting planned. (This matches our watch!). - **uniQure's AMT-130**: uniQure plans a Q3 2026 submission for its Huntington's disease gene therapy after a 180-degree turn from the FDA (which originally wanted a sham surgery-controlled trial but agreed to an externally controlled Phase 1/2 trial). (This also matches our watch!). - It mentions the transition of leadership at the FDA (noting the exit of Marty Makary and Vinay Prasad, ex-director of CBER - wait, the acting commissioner is Kyle Diamantas, and our previous notes mentioned Makary's exit. The article says: "For one, the firm noted the exit of former Commissioner Marty Makary—as well as that of Vinay Prasad, ex-director of the Center for Biologics Evaluation and Research..."). Let's check if there are other updates. Wait, let's look at the watch: - "FDA traditional approval decision on Novartis's Vanrafia (atrasentan) in IgAN" - "FDA regulatory decision on Moderna's mFlusiva mRNA flu vaccine" - "Trump's Newly Disclosed Moderna Trades Preceded FDA Advisory Panel's Unanimous Backing of mRNA Flu Vaccine" Let's search for "Trump Moderna trades mRNA flu vaccine" to see if there is a story there. Let's do a search.

Let's fetch `https://www.quiverquant.com/news/Trump%E2%80%99s+Newly+Disclosed+Moderna+Trades+Preceded+FDA+Advisory+Panel%E2%80%99s+Unanimous+Backing+of+mRNA+Flu+Vaccine` to see what is happening there. Is it from a credible source, or is it a short summary? Let's do `web_fetch`.

This is a very interesting piece of news combining politics, finance, and public health policy. Let's see: - Donald Trump's stock transaction filings (disclosed recently) show he purchased Moderna ($MRNA) stock in March 2026 (March 2 and March 17) and sold a portion on May 18. - These trades occurred before the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously (9-0) to recommend Moderna's mRNA influenza vaccine, mFlusiva (mRNA-1010), for adults aged 50 and older. - The FDA's final regulatory decision is expected by August 5, 2026 (the PDUFA date). - Since Trump's March purchases, MRNA stock has gained around 46-49%. Let's review the notes we need to write: 1. **Tregzi (Orca-T) FDA Approval**: We should write a new note for Tregzi, as it's a massive milestone: the first regulatory T (Treg) cell-based immunotherapy approved by the FDA (approved June 30, 2026). Let's name the slug `fda-approval-tregzi-orca-t-cell-therapy`. 2. **Lumvoa (veligrotug-vvze) FDA Approval**: We should write a new note for Lumvoa, as it's the first approved treatment for Thyroid Eye Disease (TED) labeled for both active and chronic TED (approved June 26, 2026). Direct competitor to Amgen's Tepezza. Let's name the slug `fda-approval-lumvoa-thyroid-eye-disease`. 3. **Casgevy Pediatric Label Expansion**: Let's update `[[fda-regulatory-pivot-advisory-committees-capricor-replimune]]` or write a new note about Casgevy's pediatric expansion to ages 2+ (approved July 1, 2026). Actually, Casgevy is a major gene therapy. Let's write a new note with stable slug `casgevy-pediatric-label-expansion-sickle-cell` since it's the first gene therapy approved for kids as young as 2 with SCD/TDT. 4. **Tolebrutinib (Cenrifki) EU Approval and FDA Divergence**: This is a great regulatory/policy update. The European Commission approved Cenrifki on June 23, 2026, while the FDA remains stalled. Let's write a new note under `tolebrutinib-eu-approval-fda-regulatory-divergence`. 5. **Duchenne Muscular Dystrophy (DMD) - Sarepta sNDAs Accepted**: This is a direct update to the post-Makary FDA pivot. The FDA accepted Sarepta's sNDAs for Amondys 45 and Vyondys 53 on June 30, 2026, despite their Phase 3 confirmatory trial failing last November. This perfectly illustrates the FDA's new leniency/pivot on rare disease drugs under acting Commissioner Kyle Diamantas. We should update the existing finding `[[fda-regulatory-pivot-advisory-committees-capricor-replimune]]` using the same slug `fda-regulatory-pivot-advisory-committees-capricor-replimune`. Wait, are there any other updates? Let's check if there are any other recent clinical trial readouts or FDA approvals. Let's do a search on "Dianthus MoMeNtum" or "MoonLake sonelokimab" or other watches to see if anything happened in the last week. Let's perform a quick search.

Wow, this is an incredible set of updates! Let's examine them carefully: 1. **MoonLake's sonelokimab in Hidradenitis Suppurativa (HS)**: - "MoonLake Reports Positive 52-Week Phase 3 Data for Sonelokimab in Hidradenitis Suppurativa" (published 1 day ago). - This relates to our watch: "MoonLake's planned Biologics License Application (BLA) submission to the FDA for sonelokimab (SLK) in moderate-to-severe hidradenitis suppurativa (HS)..." - Let's search for "MoonLake sonelokimab 52-week Phase 3 VELA data" to get the details! 2. **Dianthus claseprubart**: - Dianthus announced the initiation of the global Phase 3 EMERGE trial of claseprubart in generalized Myasthenia Gravis (gMG). This is a fresh trial initiation for claseprubart! 3. **Omeros (OMER) Faces Regulatory Setback for Narsoplimab Approval**: - "On June 26, 2026, Omeros Corporation (OMER) received an unfavorable update regarding its marketing authorization application for narsoplimab..." - This directly relates to our watch: "EMA re-examination outcome on Omeros's narsoplimab in TA-TMA" (which tracks the negative CHMP opinion and request for re-examination). - Let's search for "Omeros narsoplimab EMA update June 2026" to find out exactly what happened! 4. **Capricor's deramiocel**: - "FDA Advisory Committee Schedules Meeting to Review Deramiocel's BLA in Duchenne Muscular Dystrophy". - The FDA Cellular, Tissue, and Gene Therapies Advisory Committee meeting is scheduled for July 29, 2026. - This matches our watch: "FDA Cellular, Tissue, and Gene Therapies Advisory Committee meeting scheduled for July 29, 2026, to discuss Capricor's BLA for deramiocel in DMD cardiomyopathy." - Capricor also presented positive five-year HOPE-2 OLE data. Let's do a web search on: - "MoonLake sonelokimab VELA Phase 3 52-week" - "Omeros narsoplimab EMA June 2026" First, MoonLake's sonelokimab trial results. Let's search.

Excellent. Let's fetch `https://www.dermatologytimes.com/view/moonlake-reports-positive-52-week-phase-3-data-for-sonelokimab-in-hidradenitis-suppurativa` to get the exact numbers and details on MoonLake's sonelokimab Phase 3 VELA trial. Let's do `web_fetch`.

This is a very powerful update on MoonLake's sonelokimab in Hidradenitis Suppurativa. Let's look at the key details: - Phase 3 VELA-1 and VELA-2 dual trials. - Week 52 (1-year) data: 67.2% achieved HiSCR75; 33.1% achieved HiSCR100; 26% reached IHS4-100 (complete inflammatory remission). - Quality of Life: 15-point mean reduction in Hidradenitis Suppurativa Quality of Life (HiSQOL) scores; 46.5% achieved at least 3-point reduction in skin pain. - Adolescent data (VELA-TEEN week 24): 68% HiSCR75; 86% HiSCR50; 45% HiSCR100. - Regulatory path: BLA submission planned by end of September 2026, with a request for Priority Review. - This represents a highly successful trial completion. It directly resolves our watch! Let's make sure we record this event and update the note body or create a new note. Now let's look at Omeros's narsoplimab EMA update. Let's do a quick search.

This is a very clear and concrete regulatory setback. Let's see: - On June 26, 2026, Omeros Corporation announced that the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion on its Marketing Authorization Application (MAA) for narsoplimab (Yartemlea) in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA, or TA-TMA). - This is a major regulatory divide. Narsoplimab was approved by the US FDA in December 2025 under the brand name YARTEMLEA. - However, the EMA's CHMP remained unconvinced, citing insufficient efficacy data. - Omeros plans to request a re-examination of the negative opinion and the convening of an Ad Hoc Expert Group (AHEG). - This matches our watch! Let's fetch `https://investor.omeros.com/news/news-details/2026/Omeros-Corporation-Announces-Update-on-European-Marketing-Authorization-Application-for-Narsoplimab-in-TA-TMA/default.aspx` to get the exact details. Let's do `web_fetch`.

Perfect. We have highly detailed information. Let's summarize our findings and structure them into notes. First, let's look at the active watches/threads we can resolve or update: 1. **Omeros's request for re-examination of the negative CHMP opinion for narsoplimab in TA-TMA**: - The thread ID is `019f0620-0add-7ac7-9db1-1ce428418522`. - On June 25, 2026, the CHMP adopted a negative opinion on Omeros's MAA for narsoplimab (Yartemlea) in TA-TMA. Omeros announced this on June 26, 2026, stating that it will request a re-examination and seek review by an Ad Hoc Expert Group (AHEG). - This resolves the watch! We can call `record_event` with `resolves: false` (since it's an ongoing watch tracking the re-examination and final decision, wait, the watch description says "Monitor Omeros's request for re-examination... and the final decision," so we should keep it open or resolve it if we consider this event as the catalyst. Since the final decision is still pending, let's keep it open with `resolves: false` or update it). Actually, let's record the event on thread `019f0620-0add-7ac7-9db1-1ce428418522`. 2. **MoonLake's primary endpoint readout of the Phase 3 IZAR-1 trial of sonelokimab in psoriatic arthritis (PsA)** vs. **MoonLake's planned Biologics License Application (BLA) submission to the FDA for sonelokimab (SLK) in moderate-to-severe hidradenitis suppurativa (HS)**: - Wait, we have a watch: `019ef183-efef-70f6-9f55-cbbd11c943bb` (MoonLake BLA submission for sonelokimab in Hidradenitis Suppurativa). The trigger is "Fires when MoonLake formally submits the BLA... targeted for late September 2026." - The 52-week data readout from the VELA-1 and VELA-2 Phase 3 trials occurred on June 21, 2026 (announced June 22, 2026). - This prepares the way for the BLA submission in September 2026. We can record a watch event or write a note. Let's write a note about the 52-week VELA results. 3. **Trump's Moderna Trades and mFlusiva PDUFA**: - We have a watch `019edcf0-1d32-70e1-9a3e-6825808b2370` for the FDA regulatory decision on Moderna's mFlusiva (PDUFA date: August 5, 2026). The trades occurred in March and May 2026, preceding the VRBPAC panel recommendation. This is a great context update. Let's write the notes first. ### Note 1: Tregzi (Orca-T) FDA Approval Slug: `fda-approval-tregzi-orca-t-cell-therapy` Title: FDA Approves Tregzi (Orca-T) as First Regulatory T Cell-Based Immunotherapy for Blood Cancer Transplant Complications ### Note 2: Lumvoa (veligrotug-vvze) FDA Approval Slug: `fda-approval-lumvoa-thyroid-eye-disease` Title: FDA Approves Viridian's Lumvoa (veligrotug-vvze) as First Therapy Labeled for Both Active and Chronic Thyroid Eye Disease ### Note 3: Casgevy Pediatric Label Expansion Slug: `casgevy-pediatric-label-expansion-sickle-cell` Title: FDA Grants Rapid Supplemental Approval Expanding Casgevy Gene Therapy to Young Children Aged 2 and Older ### Note 4: Tolebrutinib (Cenrifki) EU Approval and FDA Divergence Slug: `tolebrutinib-eu-approval-fda-regulatory-divergence` Title: Tolebrutinib Wins EU Approval as First nrSPMS Disability-Targeting Therapy Amid Ongoing US Regulatory Stall ### Note 5: Post-Makary FDA Pivot (Sarepta sNDAs Accepted) Slug: `fda-regulatory-pivot-advisory-committees-capricor-replimune` Title: The Post-Makary FDA Pivot: Sarepta sNDAs Accepted and Rare Disease Leniency Under Kyle Diamantas Wait! For Note 5, we are updating the existing note `fda-regulatory-pivot-advisory-committees-capricor-replimune`. Let's make sure we reuse its slug `fda-regulatory-pivot-advisory-committees-capricor-replimune`. Let's also write a note on MoonLake's sonelokimab Phase 3 VELA trials and Omeros's narsoplimab EMA rejection. Let's see: - Omeros's narsoplimab EMA rejection: Slug `omeros-narsoplimab-ema-rejection-regulatory-divide` - MoonLake's sonelokimab 52-week data: Slug `moonlake-sonelokimab-phase-3-vela-hs-results` Let's write these notes! First, let's write Tregzi (Orca-T) FDA Approval. I will use `write_note`.

Now, I will write the note for Lumvoa (veligrotug-vvze) FDA Approval.

Now, I will write the note for Casgevy Pediatric Label Expansion.

Now, I will write the note for Tolebrutinib (Cenrifki) EU Approval and FDA Divergence.

Now, I will write the note updating `fda-regulatory-pivot-advisory-committees-capricor-replimune` (The Post-Makary FDA Pivot). This is an update to an existing note, so I will reuse the slug. Before writing, I will read the brief's instructions: "When this cycle advances a subject you already have a finding for, call write_note with that SAME slug to revise it in place". Let's do that. First, I will look at the previous content of `fda-regulatory-pivot-advisory-committees-capricor-replimune` from the relevant prior findings. It says: "The U.S. Food and Drug Administration (FDA), under acting Commissioner Kyle Diamantas, is undergoing a profound operational shift. The agency has accepted high-stakes Biologics License Application...". Let's write the updated note incorporating Sarepta's sNDA acceptance, Replimune's RP1, and uniQure's AMT-130. This is a brilliant synthesis of the FDA's rare disease leniency under acting Commissioner Kyle Diamantas. Let's write.

Now, I will write the note for MoonLake's sonelokimab Phase 3 VELA trials 1-year results. Let's write the note.

Now, I will write the note for Omeros's narsoplimab EMA Rejection. Let's write the note.

This is an outstanding collection of research notes. Let's look at the threads and watches. We have a watch event for Omeros narsoplimab: - Watch ID: `019f0620-add-7ac7-9db1-1ce428418522` (EMA re-examination outcome on Omeros's narsoplimab in TA-TMA) - Let's record an event on this watch thread to reflect that the CHMP adopted a negative opinion, which triggered Omeros's plan to request a re-examination. Let's call `record_event` with `resolves: false` (since the re-examination is ongoing). Let's do that.

Excellent! The event has been successfully recorded. What about the other threads? Let's see: - `019f0620-007b-7dab-87b4-0363a2496ea1` (FDA advisory committee meeting and PDUFA date for Replimune's RP1 in advanced melanoma). In our updated note, we mentioned that the FDA accepted the resubmission of RP1 on June 30, 2026, with an AdCom scheduled for late July and PDUFA for August 2, 2026. This is an ongoing watch, so we can keep it open. - `019f061f-f34a-7079-a276-d216329928b2` (FDA advisory committee meeting for Capricor's deramiocel in DMD cardiomyopathy). In our updated note, we mentioned that the FDA scheduled the Cellular, Tissue, and Gene Therapies Advisory Committee meeting for July 29, 2026. This is also an ongoing watch. - `019edcf0-1d32-70e1-9a3e-6825808b2370` (FDA regulatory decision on Moderna's mFlusiva mRNA flu vaccine). In our updated note, we mentioned that Trump's stock trades preceded the unanimous VRBPAC panel recommendation, and the PDUFA date is August 5, 2026. This is an ongoing watch. - `019ef183-efef-70f6-9f55-cbbd11c943bb` (MoonLake BLA submission for sonelokimab in Hidradenitis Suppurativa). In our updated note, we mentioned that MoonLake plans to submit the BLA by the end of September 2026. This is an ongoing watch. Let's call `finish_cycle` to complete this cycle. All findings are fully grounded, beautifully formatted, carrying verbatim quotes, and perfectly integrated with existing notes. No other open threads are ready to be fully resolved yet, so we will finish the cycle.

I have completed the research cycle for this week. ### Summary of Major Science and Health Policy Developments: 1. **Cell & Gene Therapy Milestones:** - **Tregzi (Orca-T) FDA Approval:** Approved on June 30, 2026, as the first-ever regulatory T (Treg) cell-based immunotherapy. In the Phase 3 PRECISION-T trial, Tregzi demonstrated a remarkable **78% chronic GVHD-free survival rate at one year** compared to just 38.4% with standard stem cell transplants. - **Casgevy Pediatric Expansion:** Granted rapid supplemental approval in just 53 days under the CNPV pilot on July 1, 2026. The CRISPR gene therapy is now approved for children as young as **2 years old** with Sickle Cell Disease or Transfusion-Dependent $\beta$-Thalassemia, opening a vital window for early intervention. 2. **Drug Approvals & Competitions:** - **Lumvoa (veligrotug-vvze) for Thyroid Eye Disease (TED):** Approved on June 26, 2026, under Priority Review. It is the **first-ever TED therapy labeled for both active and chronic disease**, posing a direct threat to Amgen's blockbuster Tepezza with a shorter 5-infusion regimen. - **Tolebrutinib nrSPMS EU Approval:** Approved in Europe on June 23, 2026, as **Cenrifki**, marking the first-ever treatment approved to target underlying disability progression in non-relapsing secondary progressive MS. This highlights a regulatory divergence, as the US FDA has stalled reviews following the failure of the Phase 3 PERSEUS trial in PPMS in late 2025. 3. **FDA Regulatory Posture Shift ("The Post-Makary Pivot"):** - Under acting Commissioner **Kyle Diamantas**, the FDA has demonstrated unprecedented leniency toward rare diseases. This is exemplified by the FDA accepting Sarepta's sNDAs for **Amondys 45** and **Vyondys 53** on June 30, 2026, seeking to convert to full approval **despite their Phase 3 confirmatory trial failing last November**. - Additionally, the FDA has scheduled high-profile Advisory Committee meetings in late July for **Replimune's RP1** (melanoma) and **Capricor's deramiocel** (DMD cardiomyopathy), and agreed to a BLA pathway for **uniQure's AMT-130** (Huntington's) without requiring sham-controlled trials. 4. **Clinical Trial Results & Regulatory Setbacks:** - **MoonLake's Sonelokimab Phase 3 VELA Results:** Final 52-week data announced on June 21, 2026, showed exceptional efficacy in moderate-to-severe HS, with **67.2% of patients achieving HiSCR75** and **33.1% reaching HiSCR100**. A BLA submission is on track for late September 2026. - **Omeros's Narsoplimab EMA Rejection:** On June 25, 2026, the EMA's CHMP adopted a negative opinion on Omeros's TA-TMA drug **Yartemlea**, citing insufficient efficacy data. This creates a major regulatory divide as the drug is already FDA-approved and commercially available in the U.S. Omeros will appeal and request a re-examination by an Ad Hoc Expert Group (AHEG).